Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing

Human amnion/chorion tissue derived from the placenta is rich in cytokines and growth factors known to promote wound healing; however, preservation of the biological activities of therapeutic allografts during processing remains a challenge. In this study, PURION® (MiMedx, Marietta, GA) processed dehydrated human amnion/chorion tissue allografts (dHACM, EpiFix®, MiMedx) were evaluated for the presence of growth factors, interleukins (ILs) and tissue inhibitors of metalloproteinases (TIMPs). Enzyme‐linked immunosorbent assays (ELISA) were performed on samples of dHACM and showed quantifiable levels of the following growth factors: platelet‐derived growth factor‐AA (PDGF‐AA), PDGF‐BB, transforming growth factor α (TGFα), TGFβ1, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), placental growth factor (PLGF) and granulocyte colony‐stimulating factor (GCSF). The ELISA assays also confirmed the presence of IL‐4, 6, 8 and 10, and TIMP 1, 2 and 4. Moreover, the relative elution of growth factors into saline from the allograft ranged from 4% to 62%, indicating that there are bound and unbound fractions of these compounds within the allograft. dHACM retained biological activities that cause human dermal fibroblast proliferation and migration of human mesenchymal stem cells (MSCs) in vitro. An in vivo mouse model showed that dHACM when tested in a skin flap model caused mesenchymal progenitor cell recruitment to the site of implantation. The results from both the in vitro and in vivo experiments clearly established that dHACM contains one or more soluble factors capable of stimulating MSC migration and recruitment. In summary, PURION® processed dHACM retains its biological activities related to wound healing, including the potential to positively affect four distinct and pivotal physiological processes intimately involved in wound healing: cell proliferation, inflammation, metalloproteinase activity and recruitment of progenitor cells. This suggests a paracrine mechanism of action for dHACM when used for wound healing applications.

[1]  O. Stojadinović,et al.  Clinical application of growth factors and cytokines in wound healing , 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[2]  D. Fetterolf,et al.  Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds , 2013, International wound journal.

[3]  T. Serena,et al.  A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers , 2013, International wound journal.

[4]  D. Fetterolf,et al.  Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. , 2012, Journal of wound care.

[5]  G. Gurtner,et al.  Therapeutic potential of bone marrow-derived mesenchymal stem cells for cutaneous wound healing , 2012, Front. Immun..

[6]  Luis Rodriguez-Menocal,et al.  Stimulation of Skin and Wound Fibroblast Migration by Mesenchymal Stem Cells Derived from Normal Donors and Chronic Wound Patients , 2012, Stem cells translational medicine.

[7]  A. Russo,et al.  The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane , 2011, Cell and Tissue Banking.

[8]  R. Kirsner,et al.  Dynamic reciprocity in the wound microenvironment , 2011, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[9]  F. Gudé,et al.  Donor age and gestational age influence on growth factor levels in human amniotic membrane , 2010, Acta ophthalmologica.

[10]  N. Gibran,et al.  Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. , 2010, Experimental cell research.

[11]  A. Landsman,et al.  Extracellular matrix biomaterials for soft tissue repair. , 2009, Clinics in podiatric medicine and surgery.

[12]  Paul G Scott,et al.  Mesenchymal Stem Cells Enhance Wound Healing Through Differentiation and Angiogenesis , 2007, Stem cells.

[13]  Thomas A. Mustoe, MD, FACS,et al.  Growth factors in wound healing. , 2003, The Surgical clinics of North America.

[14]  Thomas John,et al.  Human amniotic membrane transplantation: past, present, and future. , 2003, Ophthalmology clinics of North America.

[15]  M. Robson The role of growth factors in the healing of chronic wounds , 1997, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[16]  Robson Mc,et al.  The role of growth factors in the healing of chronic wounds , 1997, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[17]  V. Iacono,et al.  The cytokines: a review of interleukins. , 1997, Periodontal clinical investigations : official publication of the Northeastern Society of Periodontists.

[18]  W. Kenney,et al.  Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. , 1995, The Journal of clinical investigation.

[19]  D. Steed Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. , 1995, Journal of vascular surgery.

[20]  Rebeccah L. Brown,et al.  PDGF and TGF-α Act Synergistically to Improve Wound Healing in the Genetically Diabetic Mouse , 1994 .

[21]  D. M. Cooper,et al.  Determination of Endogenous Cytokines in Chronic Wounds , 1994, Annals of surgery.

[22]  L. Broemeling,et al.  The Safety and Effect of Topically Applied Recombinant Basic Fibroblast Growth Factor on the Healing of Chronic Pressure Sores , 1992, Annals of surgery.

[23]  L. Phillips,et al.  Platelet-derived growth factor BB for the treatment of chronic pressure ulcers , 1992, The Lancet.

[24]  F. Nahai,et al.  Stimulation of Healing of Chronic Wounds by Epidermal Growth Factor , 1991, Plastic and reconstructive surgery.

[25]  Gregory S. Schultz,et al.  EGF and TGF‐α in wound healing and repair , 1991 .

[26]  R. Andrassy,et al.  Epidermal growth factor and insulin act synergistically during diabetic healing. , 1990, Archives of surgery.

[27]  C. Sawhney Amniotic membrane as a biological dressing in the management of burns. , 1989, Burns : journal of the International Society for Burn Injuries.

[28]  R. Colvin,et al.  Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. , 1989, The Journal of clinical investigation.

[29]  J. Gruss,et al.  Human amniotic membrane: a versatile wound dressing. , 1978, Canadian Medical Association journal.

[30]  D. Cox,et al.  An Analysis of Transformations , 1964 .